Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07024550 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 1, 2025 to Nov 4, 2025
    • Site contact updated
    v4
  2. Start date: Jul 1, 2025 to Jul 22, 2025
    • Study title shortened, about 1 word
    v3
  3. Secondary endpoints revised (3)
    • Study description expanded, about 10 words
    • Study title expanded, about 4 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to thoroughly explore and ascertain the mechanism of action of the therapy with the EXOMIND (BTL-699-2) device in the treatment of food cravings (serving as an important precipitant to binge eating episodes), among binge eaters and to confirm its efficacy and safety, in adult binge-eating patients with food cravings. The main question it aims to answer is: To ascertain the mechanism of action of the treatment with the EXOMIND (BTL-699-2) device equipped with a BTL-699-AP-M-2 applicator in reducing food cravings, for the active group only. Participants will complete six treatments and one follow-up visit.
Trial Details
NCT Number NCT07024550
Lead Sponsor BTL Industries Ltd.
Conditions
(from sponsor)		 Binge Eating Behaviour, Binge Eating/Loss of Control Eating, Food Craving
Related terms Binge-Eating Disorder
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov